Pharma Digest

Pharma Digest

By Jan MajtaScienceLife Sciences
Download on the App Store

Pharma Digest episodes

  • Episode#9 Mar 03th 2026: BioNTech's Lean ADC Trial,
    • BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
    • UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy
    • Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
    16 min
  • Episode #8 Mar 02th 2026: Pharma Digest: Lilly's Nvidia Supercomputer

    [AI Generated AI in Pharma News]

    • Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle
    • Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs
    • XtalPi's AI + Robotics Platform Powers First Clinical Milestone for ReviR's Rare Neurological Drug RTX-117
    11 min
  • Episode #7 Mar 02th 2026: United Therapeutics' Phase 3 Win

    [AI Generated Pharma and Biotech News]

    • United Therapeutics' phase 3 win tees up filing to challenge J&J in cardiac condition
    • FDA fully releases clinical hold on Intellia CRISPR gene therapy
    • Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs
    13 min
  • Episode#6 Feb 27th 2026: AI Expansion & Healthcare Integration

    [AI Generated AI in Pharma and Biotech News]

    • QScreen AI secured CAD 500,000 in financing to expand its AI and quantum-driven health screening solutions across North America and Mexico.
    • Investment is surging in the health insurance sector, highlighted by Handl Health’s $14.2 million Series A funding for AI tools that streamline underwriting and claims management.
    • Roche and Insilico Medicine (in collaboration with Pfizer) are leading a shift toward AI-driven drug discovery, using deep learning and generative AI to identify therapeutic candidates and optimize protein engineering.
    11 min
  • Episode#5 Feb 27th 2026: Strategic Collaborations & Pipeline Shifts

    [AI Generated Pharma News]


    • Earendil Labs and WuXi XDC have partnered to integrate machine learning with the WuXiTecan-2 platform to optimize the design and targeting precision of antibody-drug conjugates (ADCs).
    • ImmVira is expanding clinical trials for MVR-T3011, a genetically engineered oncolytic virus, to treat BCG-naïve bladder cancer patients as a dual-action alternative to traditional therapies.
    • Protagonist Therapeutics exited its profit-sharing deal with Takeda for the drug rusfertide, accepting a $400 million one-time payment to independently fund its broader pipeline, including the asset ICOTYDE™.
    11 min
  • Episode#4 Feb 26th 2026

    [AI Generated Pharma News]

    • Pfizer has acquired the Chinese commercialization rights for Sciwind’s GLP-1 drug, ecnoglutide, in a deal valued at up to $495 million to target the region's growing metabolic disorder market.
    • GSK is expanding its respiratory and cardiovascular pipeline through a $950 million acquisition of 35Pharma, gaining access to a promising activin signaling inhibitor for pulmonary hypertension.
    • Novo Nordisk has entered a potential $2.1 billion partnership with Vivtex to leverage proprietary technology for developing oral formulations of biologic drugs like GLP-1 therapies.
    10 min
  • Episode#3 Feb 25th 2026

    [AI Generated AI in Drug Discovery News]

    • Dimension has secured $500 million to fund approximately 24 companies, aiming to integrate computational power with life sciences to accelerate drug discovery.
    • The BiopharmaTrend 2026 watchlist identifies startups founded in 2021 that are using AI platforms to move away from single-asset strategies toward more precise, platform-based drug development.
    • Y Combinator is backing the Yale spinout Patientdesk.ai, which utilizes "Agentic AI" to eliminate inefficiencies and improve data-driven forecasting within clinical trials.
    8 min
  • Episode#2 Feb 25th 2026

    [AI Generated AI in Drug Discovery News]

    • Turbine is utilizing a recently secured $25 million in Series B funding to advance its "lab-in-the-loop" AI platform that simulates biological processes to reduce the cost and risk of drug discovery.

    • Evinova has established strategic partnerships with AstraZeneca, Astellas, and Bristol Myers Squibb to integrate AI across the drug development spectrum, focusing on clinical trial data analysis and early-stage candidate selection.

    • Owkin has launched K Pro, an AI co-pilot that uses federated learning and biological reasoning to analyze fragmented biomedical data, aiming to significantly accelerate drug discovery timelines and enhance precision medicine.

    13 min
  • Episode#1 Feb 25th 2026

    [AI generated Pharma News]

    • Turbine's Virtual Lab: The Hungary-based firm raised $25 million to scale its AI platform that simulates cellular biology to accelerate drug discovery.
    • Global Licensing Surges: Highlighting Chinese expansion, Frontier signed a $1 billion kidney disease deal with GSK, while Harbour BioMed penned a $1.2 billion cancer treatment agreement with Solstice.
    • Astellas & Vir Partnership: A $1.7 billion collaboration focuses on VIR-5500, a prostate cancer therapy that demonstrated a 45% response rate in early trials.





    14 min

About Pharma Digest

From the publisher's feed

A fast paced, AI-generated podcast on pharma and biotech news.